CN115530381A - Protein powder for preventing prenatal depression and preparation method thereof - Google Patents

Protein powder for preventing prenatal depression and preparation method thereof Download PDF

Info

Publication number
CN115530381A
CN115530381A CN202210989391.9A CN202210989391A CN115530381A CN 115530381 A CN115530381 A CN 115530381A CN 202210989391 A CN202210989391 A CN 202210989391A CN 115530381 A CN115530381 A CN 115530381A
Authority
CN
China
Prior art keywords
vitamin
gamma
aminobutyric acid
weight ratio
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210989391.9A
Other languages
Chinese (zh)
Inventor
肖归
谢仲鹏
王静
姚欢
王虎
胡佳吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central South University
Original Assignee
Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central South University filed Critical Central South University
Priority to CN202210989391.9A priority Critical patent/CN115530381A/en
Publication of CN115530381A publication Critical patent/CN115530381A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of health-care food, in particular to protein powder for preventing prenatal depression and a preparation method thereof. The protein powder contains whey protein, soybean protein isolate, soybean phospholipid, vitamins, trace elements and active ingredients; the active ingredients comprise beta-cryptoxanthin and gamma-aminobutyric acid. The protein powder can improve sleep of pregnant women, and prevent depression.

Description

Protein powder for preventing prenatal depression and preparation method thereof
Technical Field
The invention relates to the field of health-care food, in particular to protein powder for preventing prenatal depression and a preparation method thereof.
Background
Pregnancy is one of the most happy periods of life for most women, however, in fact nearly 10% of women experience varying degrees of depression during pregnancy. Perhaps because it is believed that pregnancy is a happiness for women, even many gynecologists neglect to diagnose and treat pregnancy depression and simply resolve depression as a temporary mood disorder. In fact, depression during pregnancy is also quite dangerous if not adequately addressed and treated in time, which can affect the ability of pregnant women to attend to themselves and the fetus and can have adverse consequences for women and infants.
At present, methods for adjuvant therapy of depression are drug therapy and psychological therapy, and most of the drug therapy is based on western medicines or traditional Chinese medicine compound. Western medicines are generally mental medicines, such as fluoxetine, paroxetine and the like, and can be accompanied by side effects or generate adverse reactions after long-term administration, and addiction and drug dependence can also occur. The traditional Chinese medicine compound has slow effect, inconvenient taking, decoction and poor palatability, the traditional Chinese medicine generally needs to be taken according to symptoms, the treatment is arranged according to personal constitution, the taking contraindication is more, the convenience is greatly reduced, and simultaneously, a part of traditional Chinese medicine non-medicine and food homologous raw materials in the compound are more, and the stomach, the liver and the kidney can be damaged after long-term taking. Regardless of traditional Chinese medicines or western medicines, adverse effects can be caused to the pregnant women and the fetuses, and many pregnant women can refuse treatment to protect the fetuses, delay the treatment time and damage themselves and the fetuses.
The pregnancy is a special physiological period in the female life, the change of metabolism of the organism caused by the pregnancy greatly increases the demand of the organism for nutrition, the good nutritional state of the pregnancy can not only ensure the normal physiological function of the mother, but also ensure the normal development of the fetus, and various hidden troubles can be left if balanced nutrition is lacked. Therefore, there is a need to develop a nutritional product that can help prevent prenatal depression.
Disclosure of Invention
The invention aims to overcome the problems in the prior art and provides the protein powder for preventing the prenatal depression and the preparation method thereof.
In order to achieve the above object, the present invention provides, in a first aspect, a protein powder for preventing prenatal depression, the protein powder containing whey protein, soy protein isolate, soy phospholipids, vitamins, trace elements, and active ingredients; the active ingredients comprise beta-cryptoxanthin and gamma-aminobutyric acid.
Preferably, the milk whey protein is 20-40 parts, the soybean protein isolate is 50-80 parts, the soybean phospholipid is 5-20 parts, the vitamin is 0.5-2 parts, the trace element is 0.1-0.5 part, and the active ingredient is 1-4 parts by weight; the total weight ratio of the beta-cryptoxanthin and the gamma-aminobutyric acid in the active ingredients is 50-80%.
Preferably, the weight ratio of the β -cryptoxanthin to the γ -aminobutyric acid is from 0.5 to 2:1.
preferably, the active ingredient further comprises N-acetylneuraminic acid.
Preferably, the weight ratio of the N-acetylneuraminic acid in the active ingredients is 20-50%.
Preferably, the weight ratio of the N-acetylneuraminic acid to the gamma-aminobutyric acid is 0.8-1.5:1.
preferably, the protein powder further contains prebiotics.
Preferably, the prebiotic is selected from at least one of fructooligosaccharide, galactooligosaccharide, inulin and isomaltooligosaccharide, more preferably galactooligosaccharide.
Preferably, the weight ratio of the prebiotics to the gamma-aminobutyric acid is 0.5-1:1.
preferably, the vitamin is selected from at least one of vitamin a, vitamin C, vitamin D, vitamin E, vitamin B6 and folic acid.
Preferably, the trace element is at least one selected from the group consisting of iron, calcium, zinc and magnesium.
Preferably, the iron salt providing the iron element is sodium iron ethylenediaminetetraacetate and/or ferrous sulfate, the calcium salt providing the calcium element is calcium carbonate and/or calcium lactate, the zinc salt providing the zinc element is zinc sulfate, and the magnesium salt providing the magnesium element is magnesium sulfate.
The second aspect of the invention provides a preparation method of protein powder for preventing prenatal depression, which comprises the following steps: mixing lactalbumin, soy protein isolate, soybean phospholipid, vitamins, microelements, active ingredients, water and optionally prebiotics, ultrasonic dispersing, vacuum freeze drying, and microwave sterilizing; the active ingredients comprise beta-cryptoxanthin and gamma-aminobutyric acid.
Preferably, the milk whey protein is 20-40 parts, the soybean protein isolate is 50-80 parts, the soybean phospholipid is 5-20 parts, the vitamin is 0.5-2 parts, the trace element is 0.1-0.5 part, and the active ingredient is 1-4 parts by weight; the total weight ratio of the beta-cryptoxanthin and the gamma-aminobutyric acid in the active ingredients is 50-80%.
Preferably, the weight ratio of the β -cryptoxanthin to the γ -aminobutyric acid is from 0.5 to 2:1.
preferably, the active ingredient further comprises N-acetylneuraminic acid.
Preferably, the weight ratio of the N-acetylneuraminic acid in the active ingredients is 20-50%.
Preferably, the weight ratio of the N-acetylneuraminic acid to the gamma-aminobutyric acid is 0.8-1.5:1.
preferably, the prebiotic is selected from at least one of fructooligosaccharide, galactooligosaccharide, inulin and isomaltooligosaccharide, more preferably galactooligosaccharide.
Preferably, the weight ratio of the prebiotics to the gamma-aminobutyric acid is 0.5-1:1.
preferably, the vitamin is selected from at least one of vitamin a, vitamin C, vitamin D, vitamin E, vitamin B6 and folic acid.
Preferably, the trace elements are selected from at least one of iron, calcium, zinc and magnesium.
Preferably, the iron salt providing the iron element is sodium iron ethylenediaminetetraacetate and/or ferrous sulfate, the calcium salt providing the calcium element is calcium carbonate and/or calcium lactate, the zinc salt providing the zinc element is zinc sulfate, and the magnesium salt providing the magnesium element is magnesium sulfate.
Preferably, the miscibility comprises a first miscibility and a second miscibility; the first mixing process comprises the following steps: mixing the soy protein isolate, the soy phospholipid and water to obtain a mixture; the second mixing process comprises the following steps: mixing the mixture, the whey protein, the vitamins, the trace elements, the active ingredients and optionally prebiotics uniformly.
In a third aspect of the present invention, there is provided protein powder for preventing prenatal depression obtained by the preparation method of the second aspect.
Through the technical scheme, the invention has the beneficial effects that:
(1) The protein powder for preventing the prenatal depression can improve the sleep effect of the pregnant women by adding the active ingredients containing the beta-cryptoxanthin and the gamma-aminobutyric acid, and plays a role in preventing the depression. Moreover, the beta-cryptoxanthin and the gamma-aminobutyric acid have a synergistic effect, and a good depression preventing effect is achieved under the combined action. Whey protein, soy protein isolate, soybean lecithin, vitamins, trace elements and active ingredients containing beta-cryptoxanthin and gamma-aminobutyric acid can supplement the influence required by pregnant women and promote the growth and development of fetuses.
(2) The protein powder for preventing the antenatal depression provided by the invention has the advantages that the addition of the N-acetylneuraminic acid can further improve the action effect of the beta-cryptoxanthin and the gamma-aminobutyric acid, further improve the sleep effect of the pregnant women and play a role in preventing the depression.
Detailed Description
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For numerical ranges, each range between its endpoints and individual point values, and each individual point value can be combined with each other to give one or more new numerical ranges, and such numerical ranges should be construed as specifically disclosed herein.
The invention provides protein powder for preventing prenatal depression, which contains lactalbumin, soy protein isolate, soybean lecithin, vitamins, trace elements and active ingredients; the active ingredients comprise beta-cryptoxanthin and gamma-aminobutyric acid.
The inventor of the invention finds that the addition of active ingredients containing beta-cryptoxanthin and gamma-aminobutyric acid in the protein powder can improve the sleep effect of pregnant women and play a role in preventing depression in the research process. Moreover, the beta-cryptoxanthin and the gamma-aminobutyric acid have a synergistic effect, and can achieve a good effect of preventing depression under the combined action.
According to the invention, preferably, by weight, the whey protein is 20-40 parts, the soy protein isolate is 50-80 parts, the soybean phospholipid is 5-20 parts, the vitamin is 0.5-2 parts, the trace element is 0.1-0.5 part, and the active ingredient is 1-4 parts; the total weight ratio of the beta-cryptoxanthin and the gamma-aminobutyric acid in the active ingredients is 50-80%, and specifically can be 50%, 60%, 70%, 80%, or any value between the two values. The inventor finds that under the preferable embodiment, the whey protein, the soy protein isolate, the soybean lecithin, the vitamins, the trace elements and the active ingredient containing the beta-cryptoxanthin and the gamma-aminobutyric acid can supplement the nutrition required by the pregnant woman and promote the growth and development of a fetus, wherein the beta-cryptoxanthin and the gamma-aminobutyric acid have a synergistic effect, so that the sleep effect of the pregnant woman can be improved, and the depression can be prevented.
According to the present invention, in order to further improve the sleep effect of pregnant women, it is preferable that the weight ratio of the β -cryptoxanthin to the γ -aminobutyric acid is 0.5 to 2:1, specifically, it may be 0.5: 1. 1:1. 1.5:1. 2:1, or any value in between the two values.
According to the invention, the active ingredient preferably also contains N-acetylneuraminic acid. The inventor finds that under the preferable embodiment, the N-acetylneuraminic acid can promote the synergistic effect of the beta-cryptoxanthin and the gamma-aminobutyric acid, can further improve the sleep effect of the pregnant woman under the combined action of the N-acetylneuraminic acid, the gamma-aminobutyric acid and the beta-cryptoxanthin, plays a role in preventing depression, has multiple functions of resisting bacteria, resisting viruses, resisting inflammation, improving immunity and the like, and can play a role in protecting the pregnant woman and a fetus.
According to the present invention, in order to further improve the sleep effect of the pregnant woman, the weight ratio of the N-acetylneuraminic acid in the active ingredient is preferably 20 to 50%, and specifically may be 20%, 30%, 40%, 50%, or any value therebetween.
According to the present invention, in order to further improve the sleep effect of pregnant women, it is preferable that the weight ratio of the N-acetylneuraminic acid to the gamma-aminobutyric acid is 0.8-1.5:1, specifically, it may be 0.8: 1. 1:1. 1.5:1. or any value in between the two values.
According to the present invention, preferably, the albumen powder further contains prebiotics. The inventor finds that under the preferable embodiment, the addition of the prebiotics can improve the effect of the active ingredients, further improve the sleep effect of the pregnant women and play a role in further preventing depression; in addition, the prebiotics can improve intestinal flora, promote intestinal peristalsis and improve constipation of pregnant women.
According to the present invention, in order to further enhance the effect of the active ingredient, preferably, the prebiotic is selected from at least one of fructooligosaccharide, galactooligosaccharide, inulin, and isomaltooligosaccharide, more preferably galactooligosaccharide.
According to the present invention, in order to further enhance the action effect of the active ingredient, preferably, the weight ratio of the prebiotic to the gamma-aminobutyric acid is 0.5 to 1:1, specifically, it may be 0.5: 1. 0.6: 1. 0.7: 1. 0.8: 1. 0.9: 1. 1:1, or any value in between the two values.
According to the present invention, preferably, the vitamin is selected from at least one of vitamin a, vitamin C, vitamin D, vitamin E, vitamin B6, and folic acid. The inventors have found that in this preferred embodiment, the multivitamins can fully satisfy the nutritional needs of pregnant women, wherein folic acid can effectively prevent fetal malformations and vitamin B6 can prevent vomiting in pregnant women.
According to the present invention, preferably, the trace element is at least one selected from the group consisting of iron, calcium, zinc, and magnesium. The inventors have found that, in this preferred embodiment, the nutrients required by the pregnant woman and the fetus can be supplemented, and the development of the fetus can be promoted.
According to the present invention, in order to further promote the development of fetus, preferably, the iron salt of the iron element is provided as sodium iron ethylenediaminetetraacetate and/or ferrous sulfate, the calcium salt of the calcium element is provided as calcium carbonate and/or calcium lactate, the zinc salt of the zinc element is provided as zinc sulfate, and the magnesium salt of the magnesium element is provided as magnesium sulfate.
The above substances are all commercially available.
The second aspect of the invention provides a preparation method of protein powder for preventing prenatal depression, which comprises the following steps: mixing whey protein, soybean protein isolate, soybean phospholipid, vitamins, microelements, active ingredients, water and optionally prebiotics, ultrasonic dispersing, vacuum freeze drying, and microwave sterilizing; the active ingredients comprise beta-cryptoxanthin and gamma-aminobutyric acid.
According to the invention, preferably, by weight, the whey protein is 20-40 parts, the soy protein isolate is 50-80 parts, the soybean phospholipid is 5-20 parts, the vitamin is 0.5-2 parts, the trace elements are 0.1-0.5 part, and the active ingredient is 1-4 parts; the total weight ratio of the beta-cryptoxanthin and the gamma-aminobutyric acid in the active ingredients is 50-80%.
According to the invention, preferably, the weight ratio of said β -cryptoxanthin to said γ -aminobutyric acid is from 0.5 to 2:1.
according to the invention, the active ingredient preferably also contains N-acetylneuraminic acid.
According to the present invention, preferably, the weight ratio of the N-acetylneuraminic acid in the active ingredient is 20 to 50%.
According to the present invention, preferably, the weight ratio of the N-acetylneuraminic acid to the γ -aminobutyric acid is 0.8 to 1.5:1.
according to the present invention, preferably, the prebiotic is selected from at least one of fructooligosaccharide, galactooligosaccharide, inulin and isomaltooligosaccharide, more preferably galactooligosaccharide.
According to the invention, preferably, the weight ratio of the prebiotics to the gamma-aminobutyric acid is 0.5-1:1.
according to the present invention, preferably, the vitamin is selected from at least one of vitamin a, vitamin C, vitamin D, vitamin E, vitamin B6 and folic acid.
According to the present invention, preferably, the trace element is at least one selected from the group consisting of iron, calcium, zinc, and magnesium.
According to the present invention, preferably, the iron salt of the iron element is provided as sodium iron ethylenediaminetetraacetate and/or ferrous sulfate, the calcium salt of the calcium element is provided as calcium carbonate and/or calcium lactate, the zinc salt of the zinc element is provided as zinc sulfate, and the magnesium salt of the magnesium element is provided as magnesium sulfate.
In the invention, in order to uniformly mix and dissolve the raw materials, the raw materials can be ground to obtain ultrafine powder before mixing and dissolving. The means for abrading is not limited and may be selected as is conventional in the art.
According to the invention, in order to ensure that all components in the prepared albumen powder are uniformly distributed and avoid uncertain content of albumen powder components taken each time caused by uneven mixing, preferably, the mixing and dissolving comprises first mixing and dissolving and second mixing and dissolving; the first mixing process comprises the following steps: mixing the soy protein isolate and the soy phospholipids with water to obtain a mixture; the second mixing process comprises the following steps: mixing the mixture, the whey protein, the vitamins, the trace elements, the active ingredients and optionally prebiotics uniformly. In the present invention, the weight ratio of the total weight of the soy protein isolate and the soy lecithin to water in the first mixing process is not limited and may be selected conventionally in the art, and preferably, the weight ratio of the total weight of the soy protein isolate and the soy lecithin to water is 1:4-8, specifically 1: 4. 1: 5. 1: 6. 1: 7. 1:8, or any value in between the two values.
In the invention, the ultrasonic dispersion can uniformly disperse the raw materials. The frequency and time of ultrasonic dispersion are not limited and can be selected conventionally in the field, and illustratively, the solution after mixing is subjected to ultrasonic treatment for 0.5 to 1 hour under the condition of the frequency of 50 to 100Hz, so that the ultra-dispersed mixed solution is obtained by uniform dispersion.
In the invention, the vacuum freeze drying can avoid agglomeration among the powder. The conditions of the vacuum freeze-drying are not limited and may be conventionally selected in the art, and illustratively, the vacuum freeze-drying is carried out in a degree of vacuum of-200 Pa to-500 Pa, at a temperature of-50 ℃ to-40 ℃ and for a time of 2 to 4 hours.
In the invention, the microwave sterilization can ensure that the albumen powder is sterile and the food safety is ensured. The conditions for microwave sterilization are not limited and may be selected conventionally in the art, and for example, the temperature for microwave sterilization is 110-130 deg.C and the time is 15-30min.
In a third aspect of the present invention, there is provided protein powder for preventing prenatal depression obtained by the preparation method of the second aspect.
According to a particularly preferred embodiment of the present invention, there is provided a method for preparing protein powder for preventing prenatal depression, comprising the steps of:
(1) Mixing soybean protein isolate, soybean phospholipid and water to obtain a mixture;
(2) Adding whey protein, vitamins, trace elements, active ingredients and prebiotics into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I;
(3) Ultrasonically dispersing the mixed solution obtained in the step (2) for 0.5-1h under the condition that the frequency is 50-100Hz to obtain a mixed solution II;
(4) Carrying out vacuum freeze drying on the mixed solution obtained in the step (3) for 2-4h under the conditions that the vacuum degree is-200 Pa to-500 Pa and the temperature is-50 ℃ to-40 ℃ to obtain mixed powder;
(5) Performing microwave sterilization on the mixed powder obtained in the step (4) at the temperature of 110-130 ℃ for 15-30min to obtain protein powder;
the active ingredients comprise beta-cryptoxanthin, gamma-aminobutyric acid and N-acetylneuraminic acid; by weight, 20-40 parts of whey protein, 50-80 parts of soybean protein isolate, 5-20 parts of soybean phospholipid, 0.5-2 parts of vitamin, 0.1-0.5 part of trace element and 1-4 parts of active ingredient; the total weight ratio of the beta-cryptoxanthin to the gamma-aminobutyric acid in the active ingredients is 50-80%; the weight ratio of the N-acetylneuraminic acid, the beta-cryptoxanthin and the gamma-aminobutyric acid is 0.8-1.5:0.5-2:1; the prebiotics are galactooligosaccharides; the weight ratio of the prebiotics to the gamma-aminobutyric acid is 0.5-1:1; the vitamin is at least one selected from vitamin A, vitamin C, vitamin D, vitamin E, vitamin B6 and folic acid; the trace elements are at least one of iron elements, calcium elements and zinc elements; the iron salt for providing the iron element is sodium ferric ethylenediamine tetraacetate and/or ferrous sulfate, the calcium salt for providing the calcium element is calcium carbonate and/or calcium lactate, the zinc salt for providing the zinc element is zinc sulfate, and the magnesium salt for providing the magnesium element is magnesium sulfate.
In the above especially preferred embodiment, the addition of active ingredients containing β -cryptoxanthin, γ -aminobutyric acid and N-acetylneuraminic acid to the protein powder can improve the sleep effect of pregnant women, and has the effect of preventing depression; and the production process of the protein powder is simple and the operation is convenient.
The present invention will be described in detail below by way of examples.
In the following examples and comparative examples, β -cryptoxanthin is available from Shanghai Aladdin Biotechnology, inc. under the model number C339418; gamma-aminobutyric acid available from Shanghai Maxin Biochemical technology, inc. with model number A800350; n-acetylneuraminic acid was purchased from Shanghai Michelin Biotechnology Ltd, model No. N801293; whey protein was purchased from Shanghai Maxin Biotechnology Ltd under model number G885091; isolated soy protein was purchased from Shanghai Michelin Biochemical technology, inc. under model number S832685; the soybean phospholipids are obtained from Shanghai Merlin Biotechnology, inc. with model number of L6300; unless otherwise specified, all other materials are commercially available.
Example 1
(1) Mixing 60g of soybean protein isolate, 15g of soybean phospholipid and 450mL of water to obtain a mixture;
(2) Adding 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 1g of beta-cryptoxanthin, 1g of gamma-aminobutyric acid, 1g of N-acetylneuraminic acid and 0.8g of galactooligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I;
(3) Ultrasonically dispersing the mixed solution obtained in the step (2) for 1h under the condition that the frequency is 75Hz to obtain a mixed solution II;
(4) Carrying out vacuum freeze drying on the mixed solution obtained in the step (3) for 3h under the conditions that the vacuum degree is-400 Pa and the temperature is-45 ℃ to obtain mixed powder;
(5) And (4) performing microwave sterilization on the mixed powder obtained in the step (4) at the temperature of 120 ℃ for 20min to obtain the protein powder.
Example 2
(1) Mixing 80g of soybean protein isolate, 5g of soybean phospholipid and 340mL of water to obtain a mixture;
(2) Adding 20g of whey protein, 0.3g of folic acid, 0.3g of vitamin B6, 0.25g of ferrous sulfate, 0.25g of calcium carbonate, 0.25g of beta-cryptoxanthin, 0.5g of gamma-aminobutyric acid, 0.75g of N-acetylneuraminic acid and 0.25g of galacto-oligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I;
(3) Ultrasonically dispersing the mixed solution obtained in the step (2) for 0.5h under the condition that the frequency is 50Hz to obtain a mixed solution II;
(4) Carrying out vacuum freeze drying on the mixed solution obtained in the step (3) for 2h under the conditions that the vacuum degree is-200 Pa and the temperature is-40 ℃ to obtain mixed powder;
(5) And (5) performing microwave sterilization on the mixed powder obtained in the step (4) at the temperature of 110 ℃ for 15min to obtain the protein powder.
Example 3
(1) Mixing 50g of soybean protein isolate, 20g of soybean phospholipid and 560mL of water to obtain a mixture;
(2) Adding 40g of whey protein, 0.6g of folic acid, 0.6g of vitamin B6, 0.05g of ferrous sulfate, 0.05g of calcium carbonate, 1.5g of beta-cryptoxanthin, 0.75g of gamma-aminobutyric acid, 0.6g of N-acetylneuraminic acid and 0.75g of galacto-oligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I;
(3) Ultrasonically dispersing the mixed solution obtained in the step (2) for 1h under the condition that the frequency is 100Hz to obtain a mixed solution II;
(4) Carrying out vacuum freeze drying on the mixed solution obtained in the step (3) for 4h under the conditions that the vacuum degree is-500 Pa and the temperature is-50 ℃ to obtain mixed powder;
(5) And (5) performing microwave sterilization on the mixed powder obtained in the step (4) at the temperature of 130 ℃ for 30min to obtain the protein powder.
Example 4
Protein powder was prepared according to the method of example 1 except that step (2) was replaced with:
(2) Adding 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 0.1g of beta-cryptoxanthin, 1g of gamma-aminobutyric acid, 1g of N-acetylneuraminic acid and 0.8g of galacto-oligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I.
Example 5
Protein powder was prepared according to the method of example 1 except that step (2) was replaced with:
(2) 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 1g of beta-cryptoxanthin, 0.5g of gamma-aminobutyric acid, 1.5g of N-acetylneuraminic acid and 0.5g of galacto-oligosaccharide are added into the mixture obtained in the step (1) and uniformly mixed to obtain a mixed solution I.
Example 6
Protein powder was prepared according to the method of example 1 except that step (2) was replaced with:
(2) Adding 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 1g of beta-cryptoxanthin, 1g of gamma-aminobutyric acid and 0.8g of galacto-oligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I.
Example 7
Protein powder was prepared according to the method of example 1 except that step (2) was replaced with:
(2) Adding 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 1g of beta-cryptoxanthin, 1g of gamma-aminobutyric acid and 1g of N-acetylneuraminic acid into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I.
Example 8
(1) Mixing 60g of soybean protein isolate, 15g of soybean phospholipid, 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 1g of beta-cryptoxanthin, 1g of gamma-aminobutyric acid, 1g of N-acetylneuraminic acid and 0.8g of galacto-oligosaccharide with water, and ultrasonically dispersing for 1h under the condition of the frequency of 75Hz to obtain a mixed solution;
(2) Carrying out vacuum freeze drying on the mixed solution obtained in the step (1) for 3 hours under the conditions that the vacuum degree is-400 Pa and the temperature is-45 ℃ to obtain mixed powder;
(3) And (3) performing microwave sterilization on the mixed powder obtained in the step (2) at the temperature of 120 ℃ for 20min to obtain the protein powder.
Comparative example 1
Protein powder was prepared according to the method of example 1 except that the step (2) was replaced with:
(2) Adding 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 1g of gamma-aminobutyric acid and 0.8g of galacto-oligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I.
Comparative example 2
Protein powder was prepared according to the method of example 1 except that step (2) was replaced with:
(2) Adding 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate, 1g of beta-cryptoxanthin and 0.8g of galacto-oligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I.
Comparative example 3
Protein powder was prepared according to the method of example 1 except that step (2) was replaced with:
(2) Adding 30g of whey protein, 1g of folic acid, 1g of vitamin B6, 0.2g of ferrous sulfate, 0.2g of calcium carbonate and 0.8g of galacto-oligosaccharide into the mixture obtained in the step (1), and uniformly mixing to obtain a mixed solution I.
Test example
The mouse tail suspension test and the forced swimming test are routine animal experiments for verifying whether the drug has obvious functions of relieving anxiety and depression after administration. ICR mice, 18-22g in each male and female half, after 1 week of adaptive feeding, are randomly divided into 12 groups, 6 mice in each group are respectively fed with the protein powder prepared in the embodiment 1-the embodiment 8 and the comparative example 1-the comparative example 3, the dosage is 0.05g/kg, the medicine is prepared into suspension with physiological saline to be perfused into the stomach, and the blank control group is given with the physiological saline with the same volume during the administration. The medicine is administered for 7 days by continuous gavage 1 time a day, and the tail suspension experiment and forced swimming experiment of mice are carried out after the last administration for 1 h.
(1) Mouse tail suspension test: mainly through fixed mouse afterbody make its head hang down, the mouse is in the state that the panic and the struggle to flee for the mission in this environment, can't escape again, provides an unavoidable oppression environment for the mouse, after a period of time, the motionless time of record mouse production desperate state process that is in under this environment to observe the treatment after dosing. Adhering the tail end of a mouse to a bracket at the upper part of a tail suspension box, enabling the tail suspension box to be in an inverted suspension state, carrying out a tail suspension experiment, suspending 6 mice at one time, separating the heads of the inverted mice from the box bottom by using a partition plate so as to avoid collision, struggling the mice after being suspended, keeping the mice in a disappointed state after struggling fatigue and suspending the mice for 10 minutes, and counting the accumulated immotile time of the tail suspension inverted mice within 5 minutes, wherein the results are shown in a table 1;
(2) Forced swimming experiment: the experimental mouse is mainly placed in limited water, the mouse struggles and struggles in the environment to try to escape and cannot escape, a non-avoidable compression environment is provided, after a period of experiment, the mouse shows the immobility state of a typical behavior periscopical state, the immobility time when the mouse generates the periscopical immobility state is recorded, the treatment effect after medication is observed, the mouse is placed in a plastic swimming box with the length of 50cm, the width of 30cm and the height of 20cm to perform a forced swimming test, the time is counted for 10 minutes after the mouse is placed in the water, and the immobility time of the mouse within 5 minutes is recorded (the mouse stops struggling or shows a floating state in the water, and only small limb movement is used for keeping the head floating on the water surface), and the result is shown in table 1.
TABLE 1
Example numbering Tail suspension rest time(s) Swimming immobility time(s)
Example 1 67.2±3.2 90.3±2.4
Example 2 66.5±1.8 91.8±2.8
Example 3 67.7±2.3 91.5±3.4
Example 4 69.6±2.4 93.2±1.4
Example 5 69.8±3.1 93.8±1.6
Example 6 71.2±2.4 95.3±2.3
Example 7 70.8±1.2 96.6±3.3
Example 8 71.3±1.8 94.1±2.6
Comparative example 1 76.7±2.3 101.2±1.2
Comparative example 2 78.9±3.2 102.4±1.7
Comparative example 3 89.2±1.6 110.6±2.5
Blank control group 90.4±1.7 114.6±1.5
The results in table 1 show that the protein powder prepared by the invention can obviously reduce the immobility time in animal model mice with behavior despair, and the protein powder prepared by the invention has obvious antidepressant effect.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including combinations of various technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the scope of the invention.

Claims (10)

1. The protein powder for preventing the prenatal depression is characterized by comprising whey protein, soy protein isolate, soybean lecithin, vitamins, trace elements and active ingredients;
the active ingredients comprise beta-cryptoxanthin and gamma-aminobutyric acid.
2. The protein powder according to claim 1, wherein the whey protein is 20-40 parts, the soy protein isolate is 50-80 parts, the soy phospholipid is 5-20 parts, the vitamin is 0.5-2 parts, the trace element is 0.1-0.5 part, and the active ingredient is 1-4 parts;
the total weight ratio of the beta-cryptoxanthin to the gamma-aminobutyric acid in the active ingredients is 50-80%;
preferably, the weight ratio of said β -cryptoxanthin to said γ -aminobutyric acid is from 0.5 to 2:1;
preferably, the active ingredient further comprises N-acetylneuraminic acid;
preferably, the weight ratio of the N-acetylneuraminic acid in the active ingredients is 20-50%;
preferably, the weight ratio of the N-acetylneuraminic acid to the gamma-aminobutyric acid is 0.8-1.5:1.
3. the protein powder of claim 2, wherein the protein powder further comprises a prebiotic;
preferably, the prebiotic is selected from at least one of fructooligosaccharide, galactooligosaccharide, inulin and isomaltooligosaccharide, more preferably galactooligosaccharide;
preferably, the weight ratio of the prebiotics to the gamma-aminobutyric acid is 0.5-1:1.
4. the protein powder according to any one of claims 1 to 3, wherein the vitamin is selected from at least one of vitamin A, vitamin C, vitamin D, vitamin E, vitamin B6 and folic acid;
preferably, the trace element is at least one selected from iron, calcium, zinc and magnesium;
preferably, the iron salt providing the iron element is sodium iron ethylenediaminetetraacetate and/or ferrous sulfate, the calcium salt providing the calcium element is calcium carbonate and/or calcium lactate, the zinc salt providing the zinc element is zinc sulfate, and the magnesium salt providing the magnesium element is magnesium sulfate.
5. The preparation method of the protein powder for preventing prenatal depression is characterized by comprising the following steps: mixing lactalbumin, soy protein isolate, soybean phospholipid, vitamins, microelements, active ingredients, water and optionally prebiotics, ultrasonic dispersing, vacuum freeze drying, and microwave sterilizing;
the active ingredients contain beta-cryptoxanthin and gamma-aminobutyric acid.
6. The preparation method according to claim 5, characterized in that, by weight, the whey protein is 20-40 parts, the soy protein isolate is 50-80 parts, the soy phospholipid is 5-20 parts, the vitamin is 0.5-2 parts, the trace element is 0.1-0.5 part, and the active ingredient is 1-4 parts;
the total weight ratio of the beta-cryptoxanthin and the gamma-aminobutyric acid in the active ingredients is 50-80%;
preferably, the weight ratio of said β -cryptoxanthin to said γ -aminobutyric acid is from 0.5 to 2:1;
preferably, the active ingredient further comprises N-acetylneuraminic acid;
preferably, the weight ratio of the N-acetylneuraminic acid in the active ingredients is 20-50%;
preferably, the weight ratio of the N-acetylneuraminic acid to the gamma-aminobutyric acid is 0.8-1.5:1.
7. the method according to claim 6, wherein the prebiotic is at least one selected from the group consisting of fructooligosaccharide, galactooligosaccharide, inulin, and isomaltooligosaccharide, more preferably galactooligosaccharide;
preferably, the weight ratio of the prebiotics to the gamma-aminobutyric acid is 0.5-1:1.
8. the production method according to any one of claims 5 to 7, wherein the vitamin is at least one selected from the group consisting of vitamin A, vitamin C, vitamin D, vitamin E, vitamin B6 and folic acid;
preferably, the trace element is at least one selected from iron, calcium, zinc and magnesium;
preferably, the iron salt providing the iron element is sodium iron ethylenediaminetetraacetate and/or ferrous sulfate, the calcium salt providing the calcium element is calcium carbonate and/or calcium lactate, the zinc salt providing the zinc element is zinc sulfate, and the magnesium salt providing the magnesium element is magnesium sulfate.
9. The method according to any one of claims 5 to 7, wherein the miscibility comprises a first miscibility and a second miscibility;
the first mixing process comprises the following steps: mixing the soy protein isolate, the soy phospholipids and water to obtain a mixture; the second mixing process comprises the following steps: mixing the mixture, the whey protein, the vitamins, the trace elements, the active ingredients and optionally prebiotics uniformly.
10. Protein powder for preventing prenatal depression obtained by the preparation method of any one of claims 5 to 9.
CN202210989391.9A 2022-08-17 2022-08-17 Protein powder for preventing prenatal depression and preparation method thereof Pending CN115530381A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210989391.9A CN115530381A (en) 2022-08-17 2022-08-17 Protein powder for preventing prenatal depression and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210989391.9A CN115530381A (en) 2022-08-17 2022-08-17 Protein powder for preventing prenatal depression and preparation method thereof

Publications (1)

Publication Number Publication Date
CN115530381A true CN115530381A (en) 2022-12-30

Family

ID=84724866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210989391.9A Pending CN115530381A (en) 2022-08-17 2022-08-17 Protein powder for preventing prenatal depression and preparation method thereof

Country Status (1)

Country Link
CN (1) CN115530381A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053777A1 (en) * 1998-04-22 1999-10-28 Novartis Nutrition Ag Nutritional supplement for pregnant and lactating women
CN1953669A (en) * 2004-05-18 2007-04-25 帝斯曼知识产权资产管理有限公司 Use of beta-cryptoxanthin
CN107927732A (en) * 2017-12-15 2018-04-20 浙江中医药大学 It is a kind of to prevent depressed and senile dementia health food and preparation method thereof
CN113347893A (en) * 2019-01-23 2021-09-03 新加坡科技研究局 Prenatal beta cryptoxanthin beneficial to children
CN113908166A (en) * 2021-08-10 2022-01-11 美益添生物医药(武汉)有限公司 Use of N-acetylneuraminic acid for preparing promoter for promoting Roseburia proliferation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053777A1 (en) * 1998-04-22 1999-10-28 Novartis Nutrition Ag Nutritional supplement for pregnant and lactating women
CN1953669A (en) * 2004-05-18 2007-04-25 帝斯曼知识产权资产管理有限公司 Use of beta-cryptoxanthin
CN107927732A (en) * 2017-12-15 2018-04-20 浙江中医药大学 It is a kind of to prevent depressed and senile dementia health food and preparation method thereof
CN113347893A (en) * 2019-01-23 2021-09-03 新加坡科技研究局 Prenatal beta cryptoxanthin beneficial to children
CN113908166A (en) * 2021-08-10 2022-01-11 美益添生物医药(武汉)有限公司 Use of N-acetylneuraminic acid for preparing promoter for promoting Roseburia proliferation

Similar Documents

Publication Publication Date Title
CA2648653C (en) Fat accumulation inhibitor
CN107319525A (en) One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof
CN102845339A (en) Farming method of selenium-enriched Yellow River carp
WO2011047518A1 (en) Enteral nutrition comprising marine bioactive polysaccharide, preparation method and use thereof
JP4653269B2 (en) Theanine-containing composition
CN101711810A (en) Preparation used for improving sleep and enhancing immunity
CN102823857A (en) Ginseng donkey-hide gelatin healthcare food
CN109329902A (en) A kind of leukemia of children tailored version clinical nutrition formula and preparation method thereof
JP6859570B2 (en) Combination of 25-hydroxyvitamin D and antioxidant / anti-inflammatory agent for human functional foods
JP2002125662A (en) Non-deactivated enzyme-reinforced composition
CN102783568B (en) Feed additive
CN115530381A (en) Protein powder for preventing prenatal depression and preparation method thereof
KR101859166B1 (en) A composition for removing hangover comprising an herb extract including ginseng
CN113133531A (en) Compound protein supplement and preparation method thereof
CN103239480B (en) Calcium supplement for animals and chewable tablets of calcium supplement
CN111631305B (en) Feed additive for improving production of ewes and growth performance of lambs
CN110638842A (en) Probiotics composition for improving hyperglycemia
CN107136490A (en) A kind of peptide Chinese caterpillar fungus health product
CN108567069A (en) A kind of cultivation domestic animal ganoderma lucidum auxiliary material
CN105595020A (en) Health care feed for postpartum ewes
CN105248944A (en) Production method of potassium-rich and carotene-rich eggs
CN103766500A (en) Anti-fatigue milk tablet
CN101904400B (en) Candy favorable for relieving anorexia
CN107595829B (en) A kind of composition for preventing and treating renal osteodystrophy
CN116211882A (en) Compound caffeine pharmaceutical composition, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination